Antiviral agents - some current developments

Hypolipidaemic agents: current status and recent developments.

Current Developments in Intraspinal Agents for Cancer and Noncancer Pain

Since the late 1980s, intrathecal (IT) analgesic therapy has improved, and implantable IT drug delivery devices have become increasingly sophisticated. Physicians and patients now have myriad more options for agents and their combination, as well as for refining their delivery. As recently as 2007, The Polyanalgesic Consensus Conference of expert panelists updated its algorithm for drug selecti...

Anthelminthic agents: some recent developments and their clinical application.

Until the 1960s, the chemotherapy of human intestinal and systemic helminthiases was extremely unsatisfactory;' piperazine compounds, bephenium hydroxynaphthoate and pyrantel embonate were, for example, widely used for the former, and diethylcarbamazine (DEC), niridazole, and bithionol for the latter. Table I summarizes some important agents which have recently become available. The first of th...

Current Status Data in the 21st Century: Some Interesting Developments

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1.

Broad-spectrum antiviral agents

Development of highly effective, broad-spectrum antiviral agents is the major objective shared by the fields of virology and pharmaceutics. Antiviral drug development has focused on targeting viral entry and replication, as well as modulating cellular defense system. High throughput screening of molecules, genetic engineering of peptides, and functional screening of agents have identified promi...